机构

• 上海药物研究所 [45]
• 合肥物质科学研究院 [8]
• 上海生物化学与细胞生... [7]
• 上海营养与健康研究所 [7]
• 深圳先进技术研究院 [5]
• 武汉病毒研究所 [5]
• 更多

采集方式

• OAI收割 [86]
• iSwitch采集 [6]

内容类型

• 期刊论文 [87]
• 学位论文 [4]
• 会议论文 [1]

发表日期

• 2023 [3]
• 2022 [5]
• 2021 [2]
• 2020 [6]
• 2019 [6]
• 2018 [22]
• 更多

学科主题

• Oncology [5]
• Science & ... [2]
• Biochemist... [1]
• Biochemist... [1]
• Cell Biolo... [1]
• Computer S... [1]
• 更多

筛选

浏览/检索结果: 共92条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 From bench to bedside: current development and emerging trend of KRAS-targeted therapy 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2023, 页码: 18 作者:  Chen, Yi;  Liu, Qiu-pei;  Xie, Hua;  Ding, Jian   |  收藏  |  浏览/下载：28/0  |  提交时间：2024/01/16 KRAS mutation  KRAS(G12C) inhibitor  Pan-KRAS inhibitor  SHP2 allosteric inhibitor  SOS1 inhibitor  combination therapy   Structure-based drug discovery of novel fused- pyrazolone carboxamide derivatives as potent and selective AXL inhibitors 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2023, 卷号: 13, 期号: 12, 页码: 4918-4933 作者:  Fang, Feifei;  Dai, Yang;  Wang, Hao   |  收藏  |  浏览/下载：7/0  |  提交时间：2024/01/26 derivatives  Antitumor drug development  Potential AXL inhibitor  Antitumor activity  Structure-based drug design  Fused-pyrazolone carboxamide   Solasodine suppresses the metastasis of gastric cancer through claudin-2 via the AMPK/STAT3/NF-kappa B pathway 期刊论文  OAI收割 CHEMICO-BIOLOGICAL INTERACTIONS, 2023, 卷号: 379, 页码: 12 作者:  Su, Kexin;  Yao, Xuan;  Guo, Chenxu;  Qian, Chunmei;  Wang, Yiying   |  收藏  |  浏览/下载：17/0  |  提交时间：2023/10/17 Solasodine  Gastric cancer  Claudin-2  AMPK  EMT   ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK 期刊论文  OAI收割 FRONTIERS IN PHARMACOLOGY, 2022, 卷号: 13, 页码: 9 作者:  Song, Peiran;  Bai, Gang;  Chan, Shingpan;  Zhang, Tao;  Tong, Linjiang   |  收藏  |  浏览/下载：27/0  |  提交时间：2023/04/10 Bruton's tyrosine kinase  interleukin-2-inducible T cell kinase  ASK120067  B-cell lymphoma  T-cell leukemia   Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors 期刊论文  OAI收割 BMC Medicine, 2022, 卷号: 20, 期号: 1 作者:  Zhang,Pei;  Du,Yang;  Bai,Hua;  Wang,Zhijie;  Duan,Jianchun   |  收藏  |  浏览/下载：19/0  |  提交时间：2022/11/21 Tucidinostat  Tumor microenvironment  PD-L1  CCL5  Solid tumor   Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy 期刊论文  OAI收割 FRONTIERS IN IMMUNOLOGY, 2022, 卷号: 13, 页码: 12 作者:  Long, Yiru;  Yu, Xiaolu;  Chen, Runqiu;  Tong, Yongliang;  Gong, Likun   |  收藏  |  浏览/下载：15/0  |  提交时间：2022/08/16 noncanonical PD-1  PD-L1 axis  T-cells  tumor cells  myeloid cells  anti-PD therapy   Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma 期刊论文  OAI收割 BLOOD ADVANCES, 2022, 卷号: 6 作者:  Yang, Haiyan;  Xiang, Bing;  Song, Yuqin;  Zhang, Huilai;  Zhao, Weili   |  收藏  |  浏览/下载：24/0  |  提交时间：2022/12/23 Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2 期刊论文  OAI收割 LEUKEMIA, 2022 作者:  Yang, Jing;  Weisberg, Ellen L.;  Qi, Shuang;  Ni, Wei;  Mei, Husheng   |  收藏  |  浏览/下载：68/0  |  提交时间：2022/02/14 PDE4B Induces Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Is Transcriptionally Suppressed by CBX7 期刊论文  OAI收割 FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 卷号: 9, 页码: 12 作者:  Huang, Zhengnan;  Liu, Jiakuan;  Yang, Jiale;  Yan, Yilin;  Yang, Chenkai   |  收藏  |  浏览/下载：23/0  |  提交时间：2022/06/15 phosphodiesterase 4B  urinary bladder cancer  chromobox protein homolog 7  epithelial-to-mesenchymal transition  beta-catenin   Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 9 作者:  Zhou, Yu-bo;  Zhang, Yang-ming;  Huang, Hong-hui;  Shen, Li-jing;  Han, Xiao-feng   |  收藏  |  浏览/下载：67/0  |  提交时间：2021/11/04 multiple myeloma  HDAC inhibitor  bisthianostat  pharmacodynamics  pharmacokinetics  phase 1a clinical trial  antitumor drug